IL127038A0 - Inhibition of hiv-1 replication by antisense rna expression - Google Patents

Inhibition of hiv-1 replication by antisense rna expression

Info

Publication number
IL127038A0
IL127038A0 IL12703897A IL12703897A IL127038A0 IL 127038 A0 IL127038 A0 IL 127038A0 IL 12703897 A IL12703897 A IL 12703897A IL 12703897 A IL12703897 A IL 12703897A IL 127038 A0 IL127038 A0 IL 127038A0
Authority
IL
Israel
Prior art keywords
hiv
replication
inhibition
antisense rna
rna expression
Prior art date
Application number
IL12703897A
Original Assignee
Novartis Ag
Systemix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Systemix Inc filed Critical Novartis Ag
Publication of IL127038A0 publication Critical patent/IL127038A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12703897A 1996-06-06 1997-06-06 Inhibition of hiv-1 replication by antisense rna expression IL127038A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1923296P 1996-06-06 1996-06-06
PCT/EP1997/002952 WO1997046673A2 (en) 1996-06-06 1997-06-06 Inhibition of hiv-1 replication by antisense rna expression

Publications (1)

Publication Number Publication Date
IL127038A0 true IL127038A0 (en) 1999-09-22

Family

ID=21792127

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12703897A IL127038A0 (en) 1996-06-06 1997-06-06 Inhibition of hiv-1 replication by antisense rna expression

Country Status (7)

Country Link
EP (1) EP0914423A2 (en)
JP (1) JP2001502884A (en)
AU (1) AU717233B2 (en)
CA (1) CA2254819A1 (en)
IL (1) IL127038A0 (en)
NZ (1) NZ333190A (en)
WO (1) WO1997046673A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
AU7104200A (en) * 2000-09-01 2002-03-22 Gen Probe Inc Amplification of hiv-1 sequences for detection of sequences associated with drug-resistance mutations
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
JP5461459B2 (en) * 2011-03-01 2014-04-02 ジェン−プローブ・インコーポレーテッド Amplification of HIV-1 sequences for detection of sequences associated with drug resistance mutations
JP5461460B2 (en) * 2011-03-01 2014-04-02 ジェン−プローブ・インコーポレーテッド Amplification of HIV-1 sequences for detection of sequences associated with drug resistance mutations
JP2012105648A (en) * 2011-12-12 2012-06-07 Gen Probe Inc Amplification of hiv-1 sequence for sequence detection associated with drug resistant mutation
US9932364B2 (en) 2013-08-26 2018-04-03 The Royal Institution For The Advancement Of Learning/Mcgill University Antisense-based small RNA agents targeting the Gag open reading frame of HIV-1 RNA

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014427A2 (en) * 1989-05-25 1990-11-29 Sandoz Ltd Multivalent repressor of gene function
EP0598935A1 (en) * 1992-11-24 1994-06-01 Bayer Ag Expression vectors and their use to produce HIV-resistant human cells for therapeutic use
IL108719A0 (en) * 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them

Also Published As

Publication number Publication date
NZ333190A (en) 2001-03-30
EP0914423A2 (en) 1999-05-12
JP2001502884A (en) 2001-03-06
CA2254819A1 (en) 1997-12-11
WO1997046673A3 (en) 1998-01-15
WO1997046673A2 (en) 1997-12-11
AU717233B2 (en) 2000-03-23
AU3255897A (en) 1998-01-05

Similar Documents

Publication Publication Date Title
EP0837951A4 (en) Antisense inhibition of hepatitis b virus replication
FI944523A (en) Inhibition of papillomavirus by antisense oligonucleotide
EP0759979A4 (en) Antisense inhibition of hepatitis c virus
NZ290318A (en) Compositions comprising antisense oligonucleotides for use against hepatitis b viral replication
AU2002213002A1 (en) Antisense inhibition of caspase 6 expression
AU2001229493A1 (en) Antisense modulation of mekk2 expression
NO980720D0 (en) Pyridazine-3-one derivatives, their use and intermediates for their preparation
AU3868699A (en) Antisense modulation of rhoa expression
HUP9800634A3 (en) P-amidino-benzylamide derivatives as thrombin inhibitors, intermediates and use thereof
GB9514437D0 (en) Inhibition of gene expression
BR9609726A (en) Inhibition of gene expression
EP0861238A4 (en) Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
AU2001277003A1 (en) Antisense inhibition of her-3 expression
EP0950060A4 (en) Antisense inhibition of human adhesion molecules
IL127038A0 (en) Inhibition of hiv-1 replication by antisense rna expression
AU2001245741A1 (en) Antisense inhibition of adam10 expression
AU2585197A (en) Antisense approach to gene inhibition
AU6522599A (en) Use of a self-cleaving rna motif to modulate gene expression
NZ324118A (en) Furan-and thiophenecarbothioamide derivatives, their preparation and their use as inhibitors of the replication of hiv-1 and hiv-1 mutants
AU4425397A (en) Antisense gene therapy for rna viruses
GB9621852D0 (en) Inhibition of scale
EP0833668A4 (en) Inhibition of hepatitis b replication
ZA98347B (en) Methods for the preparation of benzophenone derivatives
AU2584395A (en) Antisense oligomers for inhibiting human papillomaviruses
PL335675A1 (en) Anticonvulsive derivatives of isoquinolinbenzamide